Compare AERT & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AERT | MBRX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 23.5M |
| IPO Year | N/A | 2016 |
| Metric | AERT | MBRX |
|---|---|---|
| Price | $0.56 | $6.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | ★ 181.3K | 140.6K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,346,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.46 | $6.01 |
| 52 Week High | $2.67 | $91.25 |
| Indicator | AERT | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 86.29 |
| Support Level | $0.53 | $6.88 |
| Resistance Level | $0.65 | $7.98 |
| Average True Range (ATR) | 0.06 | 0.42 |
| MACD | 0.00 | 0.64 |
| Stochastic Oscillator | 44.29 | 87.50 |
Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.